We enrolled 50 patients with MCL in this single-institution, single-arm, phase II clinical trial (NCT01880567). Patients with Ki-67% ≥ 50% and blastoid morphology were excluded. Ibrutinib was ...

NEW ORLEANS -- Results of a large randomized trial support the inclusion of ibrutinib (Imbruvica) to the standard first-line treatment of younger patients with mantle cell lymphoma (MCL), a researcher ...

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk ...

Patients with higher risk chronic lymphocytic leukemia can stay in remission longer with a combined treatment of the drug ibrutinib and standard care, according to new research. The study involved 85 ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed significantly longer PFS with ibrutinib plus venetoclax vs. ibrutinib plus placebo. No new ...

Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study published in Blood Advances. Targeted drugs ...

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated ...

Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially ...

New evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen can improve how long some younger people with a specific form of diffuse large B-cell ...

The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer that grows in B cells, the immune cells that make antibodies to fight infection.

ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...